- Home
- ENTA vs WLAC Comparison
ENTA vs WLAC Comparison
Compare ENTA & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- WLAC
- Stock Information
- Founded
- ENTA 1995
- WLAC 2024
- Country
- ENTA United States
- WLAC United States
- Employees
- ENTA N/A
- WLAC N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- WLAC
- Sector
- ENTA Health Care
- WLAC
- Exchange
- ENTA Nasdaq
- WLAC Nasdaq
- Market Cap
- ENTA 164.6M
- WLAC 172.6M
- IPO Year
- ENTA 2013
- WLAC 2024
- Fundamental
- Price
- ENTA $8.28
- WLAC $10.30
- Analyst Decision
- ENTA Strong Buy
- WLAC
- Analyst Count
- ENTA 4
- WLAC 0
- Target Price
- ENTA $22.25
- WLAC N/A
- AVG Volume (30 Days)
- ENTA 158.9K
- WLAC 13.3K
- Earning Date
- ENTA 08-11-2025
- WLAC 01-01-0001
- Dividend Yield
- ENTA N/A
- WLAC N/A
- EPS Growth
- ENTA N/A
- WLAC N/A
- EPS
- ENTA N/A
- WLAC N/A
- Revenue
- ENTA $64,806,000.00
- WLAC N/A
- Revenue This Year
- ENTA N/A
- WLAC N/A
- Revenue Next Year
- ENTA $1.65
- WLAC N/A
- P/E Ratio
- ENTA N/A
- WLAC $734.67
- Revenue Growth
- ENTA N/A
- WLAC N/A
- 52 Week Low
- ENTA $4.09
- WLAC $9.80
- 52 Week High
- ENTA $13.37
- WLAC $10.60
- Technical
- Relative Strength Index (RSI)
- ENTA 49.11
- WLAC N/A
- Support Level
- ENTA $8.25
- WLAC N/A
- Resistance Level
- ENTA $9.08
- WLAC N/A
- Average True Range (ATR)
- ENTA 0.44
- WLAC 0.00
- MACD
- ENTA -0.08
- WLAC 0.00
- Stochastic Oscillator
- ENTA 3.78
- WLAC 0.00
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.